hydralazine.pdf - ACTIVE LEARNING TEMPLATE Medication Jen Forbes STUDENT NAME Hydralazine MEDICATION REVIEW MODULE CHAPTER vasodilators CATEGORY

hydralazine.pdf - ACTIVE LEARNING TEMPLATE Medication Jen...

This preview shows page 1 out of 1 page.

Unformatted text preview: ACTIVE LEARNING TEMPLATE: Medication Jen Forbes STUDENT NAME______________________________________ Hydralazine MEDICATION___________________________________________________________________________ REVIEW MODULE CHAPTER____________ vasodilators CATEGORY CLASS__antihypertensives/ _____________________________________________________________________ PURPOSE OF MEDICATION Expected Pharmacological Action Direct-acting peripheral arteriolar vasodilator. Therapeutic Use Lowering of BP in hypertensive patients and decreased after load in patients with HF. Complications In a few patients, Hydralazine may produce a clinical picture simulating systemic lupus erythematosus including glomerulonephritis. This medication has teratogenic Effects Contraindications/Precautions Contraindicated in:Hypersensitivity; Some products contain tartrazine and should be avoided in patients with known intolerance. Use Cautiously in:Cardiovascular or cerebrovascular disease; Severe renal and hepatic disease (dose modification may be necessary);OB, Lactation:Has been used safely during pregnancy. Interactions Drug-Drug: increases hypotension with acute ingestion of alcohol, other anti-hypertensives,ornitrates. MAO inhibitors may exaggerate hypotension. May decrease pressor response to epinephrine. NSAIDs may decrease antihypertensive response. Betablockers decrease tachycardia from hydralazine (therapy may be combined for this rea-on).Metoprolol and propranolol increase hydralazine levels. increase blood levels of metoprolol and propranolol. Evaluation of Medication Effectiveness Decrease in BP without appearance of side effects. Decreased after load in patients with HF. ACTIVE LEARNING TEMPLATES Medication Administration PO (Adults):Hypertension—10 mg 4 times daily initially. After 2 – 4 days may increase to25 mg 4 times daily for the rest of the 1st week; may then increase to 50 mg 4 times daily (upto 300 mg/day). Once maintenance dose is established, twice-daily dosing may be used.HF—25 – 37.5 mg 4 times daily; may be increased up to 300 mg/day in 3 – 4 divided doses. IM, IV (Adults):Hypertension—5 – 40 mg repeated as needed. Eclampsia—5mg q 15 – 20 min; if no response after a total of 20 mg, consider an alternative agent.I Nursing Interventions Administer undiluted. Use solution as quickly as possible after drawing through needle into syringe. Monitor BP and pulse frequently during initial dose adjustment and periodically during therapy. About 50 – 65% of Caucasians, Black, South Indians, and Mexicans are slow acetylators at risk for toxicity, while 80 – 90% of Eskimos, Japanese, and Chinese are rapid acetylators at risk for decreased levels and treatment fail-ure. Client Education Encourage patient to comply with additional interventions for hypertension (weight reduction, low-sodium diet, smoking cessation, moderation of alcohol in-take, regular exercise, and stress management). Instruct patient and family on proper technique for BP monitoring. Advise them to check BP at least weekly and report significant changes. Therapeutic Procedure  A7 ...
View Full Document

  • Left Quote Icon

    Student Picture

  • Left Quote Icon

    Student Picture

  • Left Quote Icon

    Student Picture